Loading quotes...
Forecast
The analysts' average price target is €2.12 (+606.67%). The median is €1.82 (+506.67%).
| Buy |
Â
6 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Tenaya Therapeutics receives RMAT designation for gene therapy TN-401
The FDA has granted RMAT designation to Tenaya Therapeutics' AAV9-based gene therapy TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The decision is based on interim RIDGE-1 Phase 1b/2 data showing lower rates of premature ventricular contractions and non-sustained ventricular tachycardias. TN-401 already had Fast Track and orphan drug status; the RMAT designation enables expanded interactions with the FDA and may open accelerated approval pathways. Tenaya plans to present additional RIDGE-1 data and an update on regulatory plans for a pivotal trial in Q4 2026. » More on de.investing.com
Tenaya presents promising gene therapy data and cites liquidity through Q3 2027
At an investor conference, Tenaya reported positive early efficacy and safety data for its three clinical programs: TN-201 showed sustained improvements in six evaluable patients up to two years after a single dose, TN-401 reduced premature ventricular contractions by a median of 64%, and TN-301 is being readied for Phase II. Management is working on dose selection, regulatory alignment and development plans and expects clarity by the end of 2024. Tenaya reports cash runway through the third quarter of 2027, stressing that this provides time for several clinical and regulatory milestones before additional financing would be needed. » More on de.investing.com
Tenaya Therapeutics expects regulatory clarity and funding needs in fourth quarter
At the Canaccord Growth Conference, Tenaya reported positive early safety and efficacy signals for gene therapies TN-201 and TN-401 and the reactivation of the small‑molecule program TN-301. Regulatory decisions on the design of approval‑relevant studies for TN-201 and TN-401, as well as details on TN-301, are expected in the fourth quarter and will determine further capital allocation. The company noted cash of roughly $78 million, expected to last into the third quarter of 2027, but stressed that additional financing will be required for the planned registration and Phase II studies. » More on de.investing.com
Tenaya reports positive interim results for gene therapy TN-401 in ARVC
Tenaya presented interim results from the phase 1b/2 RIDGE‑1 study: in six patients a single infusion of TN‑401 led to a mean reduction in premature ventricular contractions of about 60–67% and the treatment was reported to be well tolerated. Biopsies showed presence of TN‑401 DNA and stable to slightly improved PKP2 protein levels; common adverse events were transient increases in troponin or transaminases. The EMA has granted TN‑401 PRIME status. Financial analyses highlight stronger liquidity than debt but note negative free cash flow, while analyst price targets range between $2 and $8. » More on de.investing.com
Tenaya Therapeutics receives Nasdaq warning over minimum share price and boosts stock plan
Tenaya Therapeutics received a warning from Nasdaq because the closing price was below $1.00 for 30 consecutive trading days; the company has until July 27, 2026 to raise the price to $1.00 or more for at least ten trading days. The board increased the shares reserved for the 2024 Inducement Equity Incentive Plan by 2,161,000 to a total of 3,361,000 shares. At the same time, Tenaya plans a $60 million capital raise (50 million units at $1.20) and announced that the FDA lifted the clinical hold on the MyPEAK-1 study of TN-201; interim results from the Phase 1b RIDGE-1 study were also released, after which analysts lowered their price targets but maintained buy ratings. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 1.5m | - |
| Gross profit | 1.5m | - |
| Net profit | -16.72m | 3.23% |
| EBITDA | -16.26m | 3.67% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €72.41m |
Number of shares | 227.93m |
52-week high/low | €1.33 - €0.27 |
| Dividends | No |
Beta | 2.88 |
P/E ratio | -0.71 |
PEG ratio | -0.02 |
P/B ratio | 1.45 |
P/S ratio | 26.25 |
Company profile
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Name | Tenaya Therapeutics |
| CEO | Faraz Ali |
| Headquarters | South San Francisco,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 30/07/2021 |
| Employees | 70 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | TNYA |